Instem Acquires PDS Life Sciences to Help Clients Bring Life Enhancing Products to Market Faster and More Efficiently
Acquisition of PDS Life Sciences Consolidates Non-Clinical Market; Further Extends Instem’s Leadership in Study Management and Regulatory SEND Submission Support
PHILADELPHIA, PA – (BUSINESS WIRE) – September 1, 2021 - Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that it has acquired PDS Life Sciences (PDS) as part of its mission to enable clients to bring their life enhancing products to market faster. This further consolidation by Instem of key application areas will help customers streamline and accelerate their research and development processes, while enabling clients to access data from across the R&D continuum, increasing the power of current and future in silico modelling and prediction solutions.
July 29, 2021 - Powerful New In Silico Models and First-to-Market Software Capabilities to Deliver Further Efficiencies and Increased Regulatory Compliance
March 22, 2021 - Instem’s Acquisition of Leading Clinical Trial Technology and Consulting Provider d-wise Represents Substantial Advancement of its Mission
March 1, 2021 - Instem’s Acquisition of Discovery Technology Solutions Provider, The Edge, Represents Another Advancement of its Mission in the Life Sciences
January 27, 2021 - High Demand for Target Safety Assessment Services and Computational Toxicology Solutions Continues Throughout Discovery and Nonclinical
RAPS U.S. Convergence 2021
September 12 - 15, 2021
September 27 - October 1, 2021
Speaker: Dr.Glenn Myatt, VP Informatics, Instem
Tuesday 28th September Session 9, 2-4pm 'Acceptance of in silico methods for regulatory purposes'